As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.
13 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast:
13 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast:
Mar '25 |
+/-
%
|
||
Revenue | 181 181 |
53%
53%
|
|
Gross Profit | 168 168 |
55%
55%
|
|
EBITDA | -14 -14 |
143%
143%
|
EBIT (Operating Income) EBIT | -47 -47 |
3,278%
3,278%
|
Net Profit | -132 -132 |
237%
237%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Todd Davis |
Employees | 68 |
Founded | 1987 |
Website | www.ligand.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.